Bristol Myers Squibb (BMY) Change in Accured Expenses (2021 - 2026)

Bristol Myers Squibb (BMY) has 6 years of Change in Accured Expenses data on file, last reported at -$3.5 billion in Q1 2026.

• Quarterly Change in Accured Expenses fell 457.42% year-over-year to -$3.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.3 billion (down 317.41% YoY) and the FY2025 annual result came in at -$441.0 million, down 129.72% from the prior year.
• Change in Accured Expenses fell to -$3.5 billion in Q1 2026 per BMY's latest filing, from -$2.4 billion in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $1.8 billion in Q3 2024 and bottomed at -$3.5 billion in Q1 2026.
• The 5-year median for Change in Accured Expenses is -$211.0 million (2023), against an average of -$65.9 million.
• Peak annual rise in Change in Accured Expenses reached 141.86% in 2022, while the deepest fall reached 676.92% in 2022.
• Tracing BMY's Change in Accured Expenses over 5 years: stood at -$303.0 million in 2022, then jumped by 30.36% to -$211.0 million in 2023, then tumbled by 91.94% to -$405.0 million in 2024, then sank by 492.1% to -$2.4 billion in 2025, then tumbled by 45.75% to -$3.5 billion in 2026.
• Per Business Quant, the three latest BMY Change in Accured Expenses figures stand at -$3.5 billion (Q1 2026), -$2.4 billion (Q4 2025), and $1.7 billion (Q3 2025).

Peer Comparison